[PDF] Top 20 Tesis diseño de una mina a cielo abierto.pdf
Has 10000 "Tesis diseño de una mina a cielo abierto.pdf" found on our website. Below are the top 20 most common "Tesis diseño de una mina a cielo abierto.pdf".
Modulation of inflammation in transgenic models of Alzheimer’s disease
... Many models that show peripheral monocytic infiltra- tion use whole body irradiation which damages the blood–brain barrier itself, induces peripheral immune ac- tivation and can facilitate ...CD11b-TK ... See full document
74
Rodent models of neuroinflammation for Alzheimer’s disease
... rodent models of LOAD that present a process of chronic neuroinflam- mation prior to tau and amyloid pathology, as described by the inflammation hypothesis of AD ...Among models of chronic ... See full document
24
Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease
... rodent models of AD with reasonable success to enhance neurogenesis and neuronal and syn- aptic plasticity ...animal models of AD [106, ...triple transgenic AD mice (3xTg-AD) that harbor mutated ... See full document
8
Exercise as a pro cognitive, pro neurogenic and anti inflammatory intervention in transgenic mouse models of Alzheimer's disease
... with cognitive and neurogenic gains) was only observed after ten weeks of running (Tapia-Rojas et al., 2016) and thus it appears that a minimum term of one month upwards of voluntary running should be considered to ... See full document
172
IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology
... The use of IVIg in AD was initially motivated by the hy- pothesis that it contains natural, polyclonal, conformation- specific antibodies against Aβ. This view is supported by the lower titer of anti-Aβ antibodies found ... See full document
99
Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer’s disease mouse model
... Strikingly, however, we also observed an equivalent over- all functional network behavior for both groups of trans- genic mice at baseline measurement during full expression of human tau, i.e. before the switch-off of ... See full document
21
Modulation of the intrinsic neuronal excitability by multifunctional liposomes tailored for the treatment of Alzheimer's disease
... on transgenic mice exposed to mApoE-PA-LIPs suggest that no apparent acute toxicity effect is exerted on the brain, at least under the experimental conditions ... See full document
10
Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?
... AbPP transgenic mice as AD models, there are reports of many manipulations that enhance or diminish the AD ...well-validated transgenic mouse model of human ...in transgenic mouse ... See full document
5
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review
... Performance-based assessment methods seem to be a promising tool, especially for patients without proxies to provide information about the patient’s IADL. Moreover, performance-based methods would overcome another ... See full document
24
Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment
... Neuroimaging Initiative study. We assessed PA and MTA on magnetic resonance imaging (MRI) using visual rating scales and retrospectively determined progression to dementia during the follow-up period of up to 3 years ... See full document
6
Cognitive reserve and clinical progression in Alzheimer diseaseA paradoxical relationship
... (median 12 months), possibly because repeated cognitive testing is more challenging at clinically advanced stages. As cognitive changes may be harder to capture over shorter follow-up durations, this could have caused a ... See full document
7
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)
... Additional inclusion criteria for all groups were age ≥ 60 years, fluent German language skills, capacity to pro- vide informed consent, and presence of a study partner. The main exclusion criteria for all groups were ... See full document
13
Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
... Elevated levels of CSF YKL-40 in early stages of AD have been demonstrated in two independent studies, but there are also contradictory data [28, 32, 40]. In our study, we confirmed that YKL-40 is elevated early in the ... See full document
8
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
... Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer ’ s disease ... See full document
12
Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer’s disease lacking functional B and T cells
... Thioflavin S staining was performed according to the standard pro- tocols as previously described ...vin S-positive amyloid plaques per mouse were ... See full document
48
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
... Likely owing to the challenges with active immunization described above, passive Aβ immunization programs are currently more numerous (Table 2). Eli Lilly and Com- pany has announced that a new phase 3 study in patients ... See full document
88
For debate: substituting placebo controls in long-term Alzheimer's prevention trials
... our models was unexpected, the specific and weighted combination of predictors is novel in the models presented: the univariate approach predicted cognitive performance (ADAScog scores) 2 years after ... See full document
58
ALZHEIMER’S DISEASE: A REVIEW
... Alzheimer's disease clinical feature typically presents with early problems in memory and visuospatial abilities (eg, becoming lost in familiar surroundings, inability to copy a geometric design on paper), yet ... See full document
121
SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment
... Sample size calculation is based on changes in our primary outcome: global cognitive function measured using the Alzheimer Disease Assessment Scale Cognitive 13 and the plus modality (ADAS-Cog 13 and plus). ... See full document
16
Parhizkar, Samira (2019): Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Dissertation, LMU München: Medizinische Fakultät
... to disease-associated protein aggregates may not simply be bystanders, but may instead contribute to AD pathogenesis (Wyss-Coray and Rogers, ...long-lasting inflammation may cause neuronal damage and death ... See full document
9
Related subjects